Literature DB >> 30411311

Vibegron: First Global Approval.

Susan J Keam1.   

Abstract

Vibegron is a selective beta 3 adrenergic receptor (β3AR) agonist that is being developed in Japan jointly by Kyorin Pharmaceutical Co., Ltd and Kissei Pharmaceutical Co., Ltd and in other regions worldwide (except in several other Asian countries) by Urovant Sciences for the treatment of overactive bladder (OAB). Based on results from Japanese phase III trials, vibegron received approval in Japan in September 2018 for this indication. This article summarizes the milestones in the development of vibegron leading to this first global approval for the treatment of OAB.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30411311     DOI： 10.1007/s40265-018-1006-3

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  4 in total

1.  Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study.

Authors:  Masaki Yoshida; Masayuki Takeda; Momokazu Gotoh; Shinji Nagai; Takafumi Kurose
Journal:  Eur Urol       Date:  2018-02-01       Impact factor: 20.096

2.  Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

Authors:  J Di Salvo; H Nagabukuro; L A Wickham; C Abbadie; J A DeMartino; A Fitzmaurice; L Gichuru; A Kulick; M J Donnelly; N Jochnowitz; A L Hurley; A Pereira; A Sanfiz; G Veronin; K Villa; J Woods; B Zamlynny; E Zycband; G M Salituro; T Frenkl; A E Weber; S D Edmondson; M Struthers
Journal:  J Pharmacol Exp Ther       Date:  2016-12-13       Impact factor: 4.030

3.  Long-term safety and efficacy of the novel β3 -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study.

Authors:  Masaki Yoshida; Hidehiro Kakizaki; Satoru Takahashi; Shinji Nagai; Takafumi Kurose
Journal:  Int J Urol       Date:  2018-05-11       Impact factor: 3.369

4.  Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.

Authors:  Scott D Edmondson; Cheng Zhu; Nam Fung Kar; Jerry Di Salvo; Hiroshi Nagabukuro; Beatrice Sacre-Salem; Karen Dingley; Richard Berger; Stephen D Goble; Gregori Morriello; Bart Harper; Christopher R Moyes; Dong-Ming Shen; Liping Wang; Richard Ball; Aileen Fitzmaurice; Tara Frenkl; Loise N Gichuru; Sookhee Ha; Amanda L Hurley; Nina Jochnowitz; Dorothy Levorse; Shruty Mistry; Randy R Miller; James Ormes; Gino M Salituro; Anthony Sanfiz; Andra S Stevenson; Katherine Villa; Beata Zamlynny; Stuart Green; Mary Struthers; Ann E Weber
Journal:  J Med Chem       Date:  2016-01-08       Impact factor: 7.446
  4 in total
  9 in total

Review 1.  Latest Advancements on Combating Obesity by Targeting Human Brown/Beige Adipose Tissues.

Authors:  Ruping Pan; Yong Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-04       Impact factor: 6.055

Review 2.  Everything You Always Wanted to Know about β3-AR * (* But Were Afraid to Ask).

Authors:  Giorgia Schena; Michael J Caplan
Journal:  Cells       Date:  2019-04-16       Impact factor: 6.600

3.  Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care.

Authors:  Mahmood Ali; Sarah Grogan; Sue Powell; Leanne Staniford; Jameel Nazir; Margarita Landeira; Patrick J O Covernton; Ashley Jaggi; Francis Fatoye; Maxine Holt
Journal:  Adv Ther       Date:  2019-09-26       Impact factor: 3.845

4.  Identification of key candidate genes and molecular pathways in white fat browning: an anti-obesity drug discovery based on computational biology.

Authors:  Yuyan Pan; Jiaqi Liu; Fazhi Qi
Journal:  Hum Genomics       Date:  2019-11-07       Impact factor: 4.639

Review 5.  Combating Obesity With Thermogenic Fat: Current Challenges and Advancements.

Authors:  Ruping Pan; Xiaohua Zhu; Pema Maretich; Yong Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-15       Impact factor: 5.555

Review 6.  Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations.

Authors:  Jan Krhut; Barbora Skugarevská; David Míka; Lars Lund; Peter Zvara
Journal:  Res Rep Urol       Date:  2022-04-26

7.  Pharmacophore-guided Virtual Screening to Identify New β3 -adrenergic Receptor Agonists.

Authors:  Navista Sri Octa Ujiantari; Seungmin Ham; Chisae Nagiri; Wataru Shihoya; Osamu Nureki; Dana Sabine Hutchinson; Daniela Schuster
Journal:  Mol Inform       Date:  2022-02-02       Impact factor: 4.050

Review 8.  Recent advances in managing overactive bladder.

Authors:  George Araklitis; Georgina Baines; Ana Sofia da Silva; Dudley Robinson; Linda Cardozo
Journal:  F1000Res       Date:  2020-09-11

Review 9.  Metabolic Improvement via Enhancing Thermogenic Fat-Mediated Non-shivering Thermogenesis: From Rodents to Humans.

Authors:  Ruping Pan; Xiaohua Zhu; Pema Maretich; Yong Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-10       Impact factor: 5.555
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.